Literature DB >> 25917728

Beyond a Simple Anesthetic Effect: Lidocaine in the Diagnosis and Treatment of Interstitial Cystitis/bladder Pain Syndrome.

Richard A Henry1, Alvaro Morales2, Catherine M Cahill3.   

Abstract

Intravesical local anesthetics, in a wide variety of combinations, are increasingly used to treat patients with interstitial cystitis-bladder pain syndrome (IC/BPS). Lidocaine has demonstrated properties that block the neuroinflammatory cycle associated with IC/BPS at many of the interactive points in this cycle. Intravesical lidocaine has been shown to assist in identifying the bladder as the source of pain in patients with pelvic pain. An appreciation of these anti-inflammatory effects and of the pharmacokinetics of intravesical lidocaine in patients with IC/BPS could lead to a safe and effective diagnosis and treatment for an as yet unidentified subset of patients in the IC/BPS spectrum.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25917728     DOI: 10.1016/j.urology.2015.01.021

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  11 in total

Review 1.  [Interstitial cystitis : Diagnosis and pharmacological and surgical therapy].

Authors:  A Gonsior; J Neuhaus; L C Horn; T Bschleipfer; J-U Stolzenburg
Journal:  Urologe A       Date:  2017-06       Impact factor: 0.639

Review 2.  Efficacy and safety comparison of pharmacotherapies for interstitial cystitis and bladder pain syndrome: a systematic review and Bayesian network meta-analysis.

Authors:  Xing-Peng Di; De-Yi Luo; Xi Jin; Wan-Yu Zhao; Hong Li; Kun-Jie Wang
Journal:  Int Urogynecol J       Date:  2021-02-27       Impact factor: 2.894

3.  Intravesical sustained release system of lidocaine and oxybutynin results from in vitro and animal study.

Authors:  David Dothan; Galiya Raisin; Nadav Malchi; Avi Gordon; Dan Touitou; Boris Chertin
Journal:  Int Urol Nephrol       Date:  2022-07-03       Impact factor: 2.266

4.  The Challenges of Interstitial Cystitis: Current Status and Future Prospects.

Authors:  Samuel Belknap; Eric Blalock; Deborah Erickson
Journal:  Drugs       Date:  2015-12       Impact factor: 9.546

Review 5.  The role of bladder instillation in the treatment of bladder pain syndrome: Is intravesical treatment an effective option for patients with bladder pain as well as LUTS?

Authors:  Giuseppe Alessandro Digesu; Visha Tailor; Alka A Bhide; Vik Khullar
Journal:  Int Urogynecol J       Date:  2020-05-01       Impact factor: 2.894

6.  Prospective comparative study of the effects of lidocaine on urodynamic and sensory parameters in bladder pain syndrome.

Authors:  Ifeoma Offiah; Elaine Dilloughery; Stephen B McMahon; Barry A O'Reilly
Journal:  Int Urogynecol J       Date:  2019-03-14       Impact factor: 2.894

7.  Notch1 Signaling Contributes to Mechanical Allodynia Associated with Cyclophosphamide-Induced Cystitis by Promoting Microglia Activation and Neuroinflammation.

Authors:  Jialiang Chen; Honglu Ding; Bolong Liu; Xiangfu Zhou; Xin Zhou; Zhijun Lin; Fei Yang; Hailun Zhan; Hengjun Xiao
Journal:  Mediators Inflamm       Date:  2021-10-04       Impact factor: 4.711

8.  Trigone as a diagnostic and therapeutic target for bladder-centric interstitial cystitis/bladder pain syndrome.

Authors:  Amy D Dobberfuhl; Stefanie van Uem; Eboo Versi
Journal:  Int Urogynecol J       Date:  2021-06-22       Impact factor: 2.894

9.  F16357, a novel protease-activated receptor 1 antagonist, improves urodynamic parameters in a rat model of interstitial cystitis.

Authors:  N Monjotin; J Gillespie; M Farrié; B Le Grand; D Junquero; N Vergnolle
Journal:  Br J Pharmacol       Date:  2016-06-03       Impact factor: 8.739

Review 10.  The enigma of men with interstitial cystitis/bladder pain syndrome.

Authors:  Hans C Arora; Daniel A Shoskes
Journal:  Transl Androl Urol       Date:  2015-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.